In a phase I/II trial of 174 advanced HCC patients treated with nivolumab who could be evaluated for PD-L1 expression, objective responses were observed in 19% of 140 patients with PD-L1 <1 and 26% of 34 patients with PD-L1 ≥1% [51].There was no significant difference in the OS rate between groups based on the expression of PD-L1. The gene discussed is CD274; the disease is hepatocellular carcinoma.